AstraZeneca Defends NJ Venue In Breast Cancer Drug Row
AstraZeneca AB blasted Mylan Laboratories Ltd.'s contention that New Jersey is the wrong venue for a patent infringement lawsuit over AstraZeneca's breast cancer drug, arguing Wednesday that it was the generic-drug...To view the full article, register now.
Already a subscriber? Click here to view full article